Inside the LBTs: evidence across aortic, PAD and BTK therapies

An overview of the late-breaking trials presented at PVI 2025 highlights key advances across aortic and peripheral interventions.

In complex fenestrated EVAR, one-year real-world data from a multicentric registry evaluating a balloon-expandable covered stent used as a bridging device in the renal–mesenteric segment show reassuring short-term safety and low target vessel instability, while longer-term outcomes remain to be established.

In femoropopliteal disease, a French real-world registry demonstrates that drug-coated balloon angioplasty is associated with significant improvements in both quality of life and walking capacity in patients with de novo lesions.

A pilot study introduces a novel implantable hydrogel sensor enabling minimally invasive, long-term monitoring of tissue oxygenation in patients with peripheral artery disease, showing safety and feasibility.

For below-the-knee disease, registry data support favorable outcomes with drug-coated balloon therapy, while in patients with chronic limb-threatening ischemia undergoing infrapopliteal bypass without suitable venous conduit, heparin-bonded grafts are associated with improved patency and sustained clinical benefit over two years compared with standard grafts.

Finally, early monocentric experience with orbital atherectomy combined with balloon angioplasty in heavily calcified below-the-knee lesions suggests the approach is safe, reproducible, and effective, with encouraging patency and limb-salvage outcomes, pending confirmation in larger studies.

Watch now to explore the full session!